Overview

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Status:
Active, not recruiting

Trial end date:
2021-10-31

Target enrollment:

Participant gender:

Summary

1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs. 4. Patients will be evaluated every 6 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Gefitinib
Imatinib Mesylate
Sunitinib